NRX Pharmaceuticals, Inc. Balance Sheet
NRXP|2 years of annual SEC 10-K data (FY2024-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 2 fiscal years. All figures from audited SEC 10-K filings.
NRX Pharmaceuticals, Inc. had $13M in total assets with negative shareholders' equity of $23M as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -5.80 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 |
|---|---|---|
| Cash & Equivalents | $7.8M | $1.4M |
| Accounts Receivable | $161.0K | - |
| Current Assets | $8.9M | $3.3M |
| PP&E (Net) | $63.0K | - |
| Goodwill | $1.8M | - |
| Total Assets | $13.0M | $3.7M |
| Current Liabilities | $28.6M | $21.9M |
| Shareholders' Equity | -$23.2M | -$11.7M |